Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Novartis AG ADR stock

Learn how to easily invest in Novartis AG ADR stock.

Novartis AG ADR is a pharmaceuticals business based in the US. Novartis AG ADR shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Novartis AG ADR employs 108,000 staff and has a trailing 12-month revenue of around $52.3 billion.

How to buy Novartis AG ADR stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – NVS. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Novartis AG ADR stock price (NYSE: NVS)

Use our graph to track the performance of NVS stocks over time.

Novartis AG ADR shares at a glance

Information last updated 2023-02-01.
Latest market close$85.85
52-week range$74.09 - $94.26
50-day moving average $90.21
200-day moving average $85.30
Wall St. target price$104.25
PE ratio 9.0175
Dividend yield $3.39 (3.71%)
Earnings per share (TTM) $9.70

Buy Novartis AG ADR stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Novartis AG ADR stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novartis AG ADR price performance over time

Historical closes compared with the close of $85.85 from 2023-02-03

1 week (2023-01-27) -4.07%
1 month (2023-01-04) -6.52%
3 months (2022-11-04) 5.05%
6 months (2022-08-04) 0.73%
1 year (2022-02-04) -0.50%
2 years (2021-02-04) -5.27%
3 years (2020-02-04) 95.1
5 years (2018-02-02) 87.2164

Is Novartis AG ADR stock undervalued or overvalued?

Valuing Novartis AG ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis AG ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novartis AG ADR's P/E ratio

Novartis AG ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Novartis AG ADR shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Novartis AG ADR's PEG ratio

Novartis AG ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.7688. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis AG ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novartis AG ADR's EBITDA

Novartis AG ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19.4 billion.

The EBITDA is a measure of a Novartis AG ADR's overall financial performance and is widely used to measure a its profitability.

Novartis AG ADR financials

Revenue TTM $52.3 billion
Operating margin TTM 27.17%
Gross profit TTM $37.4 billion
Return on assets TTM 7.41%
Return on equity TTM 36.99%
Profit margin 41.71%
Book value $28.28
Market capitalisation $189.5 billion

TTM: trailing 12 months

Novartis AG ADR share dividends


Dividend payout ratio: 72.98% of net profits

Recently Novartis AG ADR has paid out, on average, around 72.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.71% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis AG ADR shareholders could enjoy a 3.71% return on their shares, in the form of dividend payments. In Novartis AG ADR's case, that would currently equate to about $3.39 per share.

Novartis AG ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Novartis AG ADR's most recent dividend payout was on 16 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 7 March 2022 (the "ex-dividend date").

Have Novartis AG ADR's shares ever split?

Novartis AG ADR's shares were split on a 1116:1000 basis on 8 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis AG ADR shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis AG ADR shares which in turn could have impacted Novartis AG ADR's share price.

Novartis AG ADR share price volatility

Over the last 12 months, Novartis AG ADR's shares have ranged in value from as little as $74.09 up to $94.26. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis AG ADR's is 0.4929. This would suggest that Novartis AG ADR's shares are less volatile than average (for this exchange).

Novartis AG ADR overview

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc.

Frequently asked questions

What percentage of Novartis AG ADR is owned by insiders or institutions?
Currently 0.008% of Novartis AG ADR shares are held by insiders and 8.507% by institutions.
How many people work for Novartis AG ADR?
Latest data suggests 108,000 work at Novartis AG ADR.
When does the fiscal year end for Novartis AG ADR?
Novartis AG ADR's fiscal year ends in December.
Where is Novartis AG ADR based?
Novartis AG ADR's address is: Lichtstrasse 35, Basel, Switzerland, 4056
What is Novartis AG ADR's ISIN number?
Novartis AG ADR's international securities identification number is: US66987V1098
What is Novartis AG ADR's CUSIP number?
Novartis AG ADR's Committee on Uniform Securities Identification Procedures number is: 66987V109

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site